The dual role of empagliflozin: Cardio renal protection in T2DM patients

被引：3

作者：

Shafiq, Aimen ^{[1
]}

Mahboob, Eman ^{[1
]}

Samad, Muhammad Ammar ^{[1
]}

Rehman, Mohammad Hassam Ur ^{[1
]}

Tharwani, Zoaib Habib ^{[1
]}

机构：

[1] Dow Univ Hlth Sci, Dow Med Coll, Fac Med, Karachi, Pakistan

来源：

ANNALS OF MEDICINE AND SURGERY | 2022年 / 81卷

关键词：

Empagliflozin; Type 2 diabetes mellitus; Cardio protective; Reno protective; Side effects; COTRANSPORTER; 2; INHIBITOR; TYPE-2; DIABETES-MELLITUS; ESTABLISHED CARDIOVASCULAR-DISEASE; BETA-CELL DYSFUNCTION; DOUBLE-BLIND; SGLT2; INHIBITORS; ADD-ON; KIDNEY-DISEASE; OUTCOMES; RISK;

D O I：

10.1016/j.amsu.2022.104555

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Empagliflozin (Jardiance (R)) is an insulin independent antihyperglycemic agent used in treatment of T2D.The drug is a sodium glucose cotransporter-2 (SGLT2) inhibitor approved in USA and Europe and other countries of the world. As empagliflozin demonstrates cardioprotective and Reno protective properties its prime target are patients having CVD and CKD complicated by T2D. This review sheds light on mechanism of action of the drug and with the help of clinical outcomes establishes the use of empagliflozin in T2D patients.Although empagliflozin is a well-tolerated and easy to administer drug, it has some side effects and contraindications which are discussed in the article to help the reader weigh its beneficial effects against its adverse effect and understand its use in clinical medicine.

引用

页数：6

共 50 条

[31] Insufficient Plasma Melatonin and Its Association With Neuropsychiatric Impairments in Patients With T2DM
He, Shuai
Yu, Yue
Chen, Peng-quan
Sun, Hui-min
Gao, Xin-ran
Sun, Huai-zhi
Ge, Jin-fang
JOURNAL OF DIABETES RESEARCH, 2024, 2024
[32] T2DM/CKD genetic risk scores and the progression of diabetic kidney disease in T2DM subjects
Galuska, David
Pacal, Lukas
Chalasova, Katarina
Divacka, Petra
Rehorova, Jitka
Svojanovsky, Jan
Hubacek, Jaroslav A.
Lanska, Vera
Kankova, Katerina
GENE, 2024, 927
[33] Comorbidity Analysis between Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared Pathways and the Role of T2DM Drugs
Karki, Reagon
Kodamullil, Alpha Tom
Hofmann-Apitius, Martin
JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (02) : 721 - 731
[34] Metabolic and renal outcomes of empagliflozin in patients with type 2 diabetes mellitus attending Armed Forces Hospital in Saudi Arabia
Alshahrani, Ali A.
Al Qahtani, Saad S.
Al Qahtani, Abrar S.
Mashhour, Saeed M.
Alkhtani, Zayed S.
Alragea, Yahya M.
SAUDI MEDICAL JOURNAL, 2023, 44 (07) : 674 - 678
[35] Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
Abdul-Ghani, Muhammad
Jayyous, Amin
Asaad, Nidal
Helmy, Sherif
Al-Suwaidi, Jassim
ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (10)
[36] Inpatient Management of T2DM and Hyperglycemia in Older Adults
DeCarlo, Kristen
Wallia, Amisha
CURRENT DIABETES REPORTS, 2019, 19 (10)
[37] Basal insulin persistence in Brazilian participants with T2DM
Franco, Denise Reis
Perez-Nieves, Magaly
Ivanova, Jasmina I.
Cao, Dachuang
Caselato Vaz, Marcela Saturnino
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2019, 65 (10): : 1254 - 1264
[38] Evaluation of T2DM related knowledge and practices of Omani patients
Al Bimani, Zeyana S.
Khan, Shah Alam
David, Pratap
SAUDI PHARMACEUTICAL JOURNAL, 2015, 23 (01) : 22 - 27
[39] Dietary Knowledge, Attitude and Practice (KAP) Among the Family Members of Patients with Type 2 Diabetes Mellitus (T2DM) and Its Influence on the KAP of T2DM Patients
Hu, Xiling
Zhang, Yao
Lin, Shuo
Guo, Xiaodi
Yang, Dan
Cai, Mengyin
Gao, Lingling
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2021, 14 : 205 - 213
[40] Sodium-Glucose Cotransporter-2 Inhibitors and Diabetic-Ketoacidosis in T2DM Patients: An Updated Meta-Analysis and a Mendelian Randomization Analysis
Wang, Yufei
Qin, Yuhan
Zhang, Jing
Wu, Anhu
Qin, Xiaohan
Du, Le
Zhang, Huabing
Guo, Xiaoxiao
Zhang, Shuyang
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,

← 1 2 3 4 5 →